Abstract
Free access to this special issue has been made possible by the financial support of the 1st Annual Treatment as Prevention (TasP) Workshop, held May 4-6, 2011 in Vancouver, British Columbia (BC), Canada. The Workshop was organised and hosted by the BC Centre for Excellence in HIV/AIDS and co-hosted by the International AIDS Society, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the World Health Organization and the National Institute on Drug Abuse. Co-sponsors include the National Institutes of Health Office of AIDS Research, the National Institute of Allergy and Infectious Diseases, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), the Bill & Melinda Gates Foundation, the Canadian Institutes for Health Research and the Public Health Agency of Canada. Academic partners included the University of British Columbia, Simon Fraser University, Vancouver Coastal Health Authority and Providence Health Care, Vancouver. Industry sponsors included Bristol- Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. Additional Industry supporters included Abbott Laboratories and Biolytical.
Current HIV Research
Title: Acknowledgements and Editorial (Exploring the Role of “Treatment as Prevention”)
Volume: 9 Issue: 6
Author(s): Marianne Harris and Julio S.G. Montaner
Affiliation:
Abstract: Free access to this special issue has been made possible by the financial support of the 1st Annual Treatment as Prevention (TasP) Workshop, held May 4-6, 2011 in Vancouver, British Columbia (BC), Canada. The Workshop was organised and hosted by the BC Centre for Excellence in HIV/AIDS and co-hosted by the International AIDS Society, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the World Health Organization and the National Institute on Drug Abuse. Co-sponsors include the National Institutes of Health Office of AIDS Research, the National Institute of Allergy and Infectious Diseases, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), the Bill & Melinda Gates Foundation, the Canadian Institutes for Health Research and the Public Health Agency of Canada. Academic partners included the University of British Columbia, Simon Fraser University, Vancouver Coastal Health Authority and Providence Health Care, Vancouver. Industry sponsors included Bristol- Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. Additional Industry supporters included Abbott Laboratories and Biolytical.
Export Options
About this article
Cite this article as:
Harris Marianne and S.G. Montaner Julio, Acknowledgements and Editorial (Exploring the Role of “Treatment as Prevention”), Current HIV Research 2011; 9 (6) . https://dx.doi.org/10.2174/157016211798038560
DOI https://dx.doi.org/10.2174/157016211798038560 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Focus on Pleiotropic Role of HMGB1 in the Onset of Allergic and Non- Allergic Respiratory Diseases
Current Respiratory Medicine Reviews The β and γ Classes of Carbonic Anhydrase
Current Pharmaceutical Design Characterization of Radiolabeled Dry Powder Leucine, a Constituent of Inhalable Capreomycin
Drug Delivery Letters Recent Advancement in Predicting Subcellular Localization of Mycobacterial Protein with Machine Learning Methods
Medicinal Chemistry Identification of Active Phytochemical from Traditional Herbal Knowledge-base Targeting Pantothenate Synthetase for Anti-tuberculosis Therapy
Letters in Drug Design & Discovery Structural Biology of Bacterial Secretion Systems in Gram-Negative Pathogens- Potential for New Drug Targets
Infectious Disorders - Drug Targets Synthesis and Assessment of 3-Substituted Phenazines as Novel Antichlamydial Agents
Medicinal Chemistry In Silico Identification of Human miR 3654 and its Targets Revealed its Involvement in Prostate Cancer Progression
MicroRNA Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease
Current Pharmaceutical Design Efficacy, Tolerability and Virological Consequences of Long-Term Use of Unboosted Atazanavir Plus 2 NRTIs in HIV-Infected Patients
Current HIV Research Applications of Molecular Simulation in the Discovery of Antituberculosis Drugs: A Review
Protein & Peptide Letters Synthesis and Evaluation of New Thiazole Derivatives as Potential Antimicrobial Agents
Letters in Drug Design & Discovery Structural Analysis of Farnesyl Pyrophosphate Synthase from Parasitic Protozoa, a Potential Chemotherapeutic Target
Infectious Disorders - Drug Targets Isoprenoid Metabolism as a Therapeutic Target in Gram-Negative Pathogens
Current Topics in Medicinal Chemistry Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry α-Glucan Pathway as a Novel Mtb Drug Target: Structural Insights and Cues for Polypharmcological Targeting of GlgB and GlgE
Current Medicinal Chemistry Predictive and Prognostic Value of Ascitic Fluid Mannose Binding Lectin in Patients with Spontaneous Bacterial Peritonitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advances in Peptide Nucleic Acids as Antibacterial Agents
Current Medicinal Chemistry Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy